Financials (USD)
Sales 2024 * | 530M | Sales 2025 * | 679M | Capitalization | 3.16B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 121M | EV / Sales 2024 * | 6.23 x |
Net Debt 2024 * | 139M | Net Debt 2025 * | 24.31M | EV / Sales 2025 * | 4.69 x |
P/E ratio 2024 * |
-3,141
x | P/E ratio 2025 * |
27.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.75% |
Latest transcript on Amicus Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
1st Jan change | Capi. | |
---|---|---|
+3.13% | 43.43B | |
+48.88% | 41.69B | |
+8.49% | 41.31B | |
-10.82% | 27.14B | |
+8.26% | 25.28B | |
-23.69% | 18.47B | |
+1.58% | 12.33B | |
+32.83% | 12.59B | |
+6.63% | 11.03B |